|
|
|
|
¡¡ |
|
¡¡ |
|
|
|
¡¡ |
HOME > ÇÐȸ°£Ç๰ >
¿ë¾î»çÀü |
|
Á¦¸ñ |
ÇѼ¾»ç¾÷´ë»óÀÚÀÇ Æ÷µµ´ç-6-ÀλêÅ»¼ö¼ÒÈ¿¼Ò °áÇÌ Æò°¡ |
|
|
|
|
ÀúÀÚ |
±èÀ±Áö, ¹ÚÁøÈ£, ±èÁ¾ÇÊ |
¼Ò¼Ó |
Çѱ¹ÇѼ¾º¹ÁöÇùȸ ¿¬±¸¿ø |
|
|
³âµµ |
2020 |
±Ç |
53 |
|
|
È£ |
1 |
¹øÈ£ |
4 |
|
|
½ÃÀÛÆäÀÌÁö |
35 |
³¡ÆäÀÌÁö |
42 |
|
|
÷ºÎ |
Æ÷µµ´ç-6-ÀλêÅ»¼ö¼ÒÈ¿¼Ò °áÇÌ Æò°¡.pdf |
|
|
¿ä¾à |
In this study, we detected that the prevalence of deficiency and gene mutation was low, thus inferred that anemia was relatively less relevant to deficiency in persons affected by Hansen¡¯sdisease. However, the number of participant in our study is small, and many studies reported that deficiency test should be performed before the dapsone administration, therefore, we suggest that continuous monitoring of patients with Hansen¡¯s disease is necessary.
▪ Key words : Glucose-6-phosphate dehydrogenase deficiency, |
|
|
³»¿ë |
|
| |
¡¡ |
|
|
|
|
|
|
|
|